GLP-1 side effects, ranked by frequency
Nausea is the headline. The full picture from registration trials includes diarrhea, fatigue, gallstones, and a few rare-but-serious events worth knowing about before you start.
About one in three patients quits a GLP-1 within the first six months. The most common reason is not cost or weight-loss disappointment. It is GI side effects.
This post ranks the side effects you'll actually encounter, from most-common to most-serious, with the realistic % chance of each.
Most common (>20% of patients)
Nausea (~44% on Wegovy, ~29% on Zepbound): The defining GLP-1 side effect. Worst during dose titration; usually subsides 1-2 weeks after each dose increase. Mostly mild-to-moderate. Eat smaller meals, avoid greasy or rich food, time injections for early in the week so the worst hits during workdays you can sleep through.
Diarrhea (~31% Wegovy, ~23% Zepbound): Second most common. Often follows nausea or pairs with it. Hydration matters more than diet here; many patients underestimate how much fluid they're losing while their appetite is suppressed.
Constipation (~23% Wegovy, ~17% Zepbound): The other half of GI side effects. The medication slows gastric emptying, so motility slows everywhere. Fiber and water solve most cases; stool softeners work for the stubborn ones. About 5% of patients oscillate between diarrhea and constipation.
Vomiting (~25% Wegovy, ~12% Zepbound): More common with Wegovy than Zepbound. Most pronounced when starting or escalating dose. If you're vomiting more than 1-2 times per week, your dose is probably too high or you're escalating too fast.
Common (5-20%)
Fatigue / low energy (~11% on Wegovy): Often dietary — patients eat ~30-40% fewer calories on a GLP-1 and don't always replace the lost macronutrients. A protein-forward diet (1g per kg of bodyweight per day) addresses most cases.
Headache (~14% on Wegovy): Mild and usually self-resolving. Can be dehydration-driven; check water intake first.
Heartburn / acid reflux (~5-10%): Slowed gastric emptying means food sits longer; reflux can worsen. Avoid eating 3 hours before lying down; PPIs help if persistent.
Injection site reactions (~5%): Redness, itching, or small lumps at the injection site. Rotate injection sites; usually resolves within a few days.
Less common but worth knowing (1-5%)
Gallstones / cholecystitis (~1.6% Wegovy vs 0.7% placebo): Rapid weight loss is associated with gallstone formation regardless of mechanism. GLP-1s appear to slightly increase risk above the baseline weight-loss-driven rate. Cholecystectomy is the standard fix when symptomatic. If you have a known gallbladder issue, flag it to your prescriber before starting.
Gastroparesis (delayed gastric emptying, severe form): ~1% of patients develop more pronounced gastric emptying delay than expected. Symptoms include feeling full hours after eating, persistent vomiting of undigested food, abdominal pain. Usually reversible after stopping the medication, but can persist in rare cases. This was the basis of high-profile lawsuits in 2023-2024.
Pancreatitis (~0.2-0.4%): Rare but serious. Symptoms: severe upper abdominal pain radiating to back, vomiting, fever. Stop the medication immediately and seek care. Risk increases in patients with prior pancreatitis history; most prescribers screen for this at intake.
Hair loss / thinning (~3-5%, anecdotal): Not in registration trial side-effect tables but well-documented in patient communities. Usually telogen effluvium driven by rapid weight loss and reduced caloric intake rather than the medication itself. Reverses 3-6 months after weight stabilizes; biotin and adequate protein intake help.
Rare but serious (<1%)
Medullary thyroid carcinoma (MTC): Black-box warning on all GLP-1 receptor agonists based on rodent studies. No human signal has emerged in 15+ years of post-market use. Patients with personal or family history of MTC or MEN2 syndrome should not take GLP-1s.
Severe hypoglycemia (very rare in non-diabetics): GLP-1s have a low intrinsic hypoglycemia risk because they're glucose-dependent. Risk increases for patients on sulfonylureas or insulin. Non-diabetic weight-loss patients essentially never experience clinically significant hypoglycemia.
Diabetic retinopathy worsening: Specifically observed in long-term diabetic patients on semaglutide; rapid HbA1c reduction can transiently worsen retinopathy. Not relevant for most weight-loss-only patients.
Severe allergic reactions / anaphylaxis: Reported in <0.1%. Stop and seek emergency care if you develop hives, swelling, or breathing difficulty after injection.
What this means for program choice
Most side effects are dose-titration phenomena. Programs that titrate slower (Noom Med's microdose protocol, Form Health's clinician-driven titration) tend to have lower discontinuation rates. Programs that escalate fast (some async-only providers) may produce more side-effect-driven dropouts.
If you're starting GLP-1 and worried about side effects, ask whether your program offers dose holds (staying at a tolerable dose for an extra month before escalating) without insurance complications. Form Health, 9amHealth, and Knownwell all explicitly support clinician-led titration adjustments. Async-only flat-rate providers can usually accommodate dose holds but you may need to ask explicitly.